Kicking the Tires 2: Life Sciences and FDA Diligence

In the second episode in our Health Care & Life Sciences M&A Webinar Series, we discussed major areas of regulatory risk in acquiring businesses in the life sciences industry and/or regulated by food and drug law. Discussion topics included:

• FDA pharmaceutical approvals
• FDA device approvals
• FDA enforcement/recall/notice letter activity
• Fraud and abuse issues
• Post-acquisition integration issues
• Government reimbursement and policy issues
• Third party issues
• Supply chain issues

Listen to the webinar here. Listen to a recording from the first webinar “Kicking the Tires 1: Key Regulatory Diligence Considerations” here.

View the full series schedule here.